In the 1980s, high-dose interleukin-2 (IL-2) was used successfully in renal cell cancer, producing a prolonged and durable response along with overall survival benefit in a small subset of patients [6,7]. The gene discussed is IL2; the disease is renal cell adenocarcinoma.